Swedish pharmaceutical company Xspray Pharma AB (STO:XSPRAY) said on Thursday that the US Food and Drug Administration (FDA) has agreed to review the company's application for market approval for its product candidate Dasynoc (dasatinib).
This application consists of the results from registrational studies on healthy volunteers, where bioequivalence was achieved at an approximately 30% lower dosage than the reference product Sprycel. The application includes Dasynoc for the treatment of acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML), which are blood cancer illnesses in an area where only one new drug has been registered over a ten-year period, the company said.
Subject to approval from the FDA, Xspray Pharma estimates that Dasynoc could be launched in the US market in 2023.
Pfizer and BioNTech granted US EUA for booster dose of their COVID-19 vaccine in children 5 to 11
First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors
Wysa Receives FDA Breakthrough Device Designation for AI-led Mental Health Conversational Agent
Paige AI Solution for Prostate Cancer Biomarker Detection Receives CE-IVD and UKCA Marks
Inmagene Biopharmaceuticals' IMG-004 investigational new drug application receives US FDA approval
Mitsubishi Tanabe Pharma America's RADICAVA ORS receives US FDA approval
Hologic Receives FDA Approval of Aptima CMV Quant Assay for Human Cytomegalovirus